Analysts See Significant Upside for Alto Neuroscience, With Fair Value Estimate 58% Above Current Trading Price
A new discounted cash flow analysis suggests shares of the clinical-stage biotech Alto Neuroscience could be substantially undervalued, presenting a potential opportunity for investors as the company advances its brain disorder therapeutics.